Active, Not Recruiting
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
NCT03283137
- Conditions
- B-cell Non Hodgkin Lymphoma, CLL, Hemic and Lymphatic Diseases, +9 more
- Locations
-
- Yale University New Haven, Connecticut, United States
- University of Chicago Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center New York, United States